Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 11/20 | 1.00 |
| ▸ | MEN1 | O00255 | 8/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.65 |
| ▸ | MAPT | P10636 | 8/20 | 0.65 |
| ▸ | HPGD | P15428 | 6/20 | 0.65 |
| ▸ | LMNA | P02545 | 5/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.65 |
| ▸ | NFKB1 | P19838 | 5/20 | 0.65 |
| ▸ | BLM | P54132 | 5/20 | 0.65 |
| ▸ | PMP22 | Q01453 | 5/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.65 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.65 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.65 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.65 |
| ▸ | TSHR | P16473 | 4/20 | 0.65 |
| ▸ | RGS12 | O14924 | 3/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6213178 | 0.86 | EGFR (0.74) | EGFRMEN1KMT2AALDH1A1MAPT | |
| Tyrphostin 25 SCHEMBL239879 | 0.79 | EGFR (1.00) | EGFRMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL8543873 | 0.79 | EGFR (0.64) | EGFRMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL1238796 | 0.76 | MEN1 (1.00) | EGFRMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL12617223 | 0.76 | EGFR (0.70) | EGFRMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL3248262 | 0.76 | EGFR (0.82) | EGFRMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL8745026 | 0.76 | EGFR (0.87) | EGFRMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL15286525 | 0.74 | EGFR (0.59) | EGFRMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL27183485 | 0.74 | EGFR (0.59) | EGFRMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL27960908 | 0.74 | ALDH1A1 (0.67) | EGFRMEN1KMT2AALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0614661-A2 | Benzylidene- and cinnamylidine-malononitrile derivatives for the inhibition of proliferative processes in mammalian cells | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 1994-09-14 | — | — | EP | claimed |
| EP-0403238-A2 | Cosmetic composition | UNILEVER PLC (GB) | 1990-12-19 | — | — | EP | claimed |
| EP-0322738-A2 | Benzylidene-malononitrile derivatives for the inhibition of proliferative processes in mammalian cells | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 1989-07-05 | — | — | EP | claimed |
| JP-10279477-A | — | — | None | — | — | JP | disclosed |
| US-20240066001-A1 | METHODS AND COMPOSITIONS FOR TREATING OBESITY, PREVENTING WEIGHT GAIN, PROMOTING WEIGHT LOSS, PROMOTING SLIMMING, OR TREATING OR PREVENTING THE DEVELOPMENT OF DIABETES | SILTI AG (CH) | 2024-02-29 | — | — | US | disclosed |
| EP-3164125-B1 | METHODS AND COMPOSITIONS FOR TREATING OBESITY, PREVENTING WEIGHT GAIN, PROMOTING WEIGHT LOSS, PROMOTING SLIMMING, OR TREATING OR PREVENTING THE DEVELOPMENT OF DIABETES | NAN GLOBAL LLC (US) | 2023-09-06 | — | — | EP | disclosed |
| CN-113387836-A | Methods and compositions for treating obesity, preventing weight gain, promoting weight loss, or treating or preventing the development of diabetes | NAN全球有限责任公司 | 2021-09-14 | — | — | CN | disclosed |
| CN-106604725-B | Methods and compositions for treating obesity, preventing weight gain, promoting weight loss, or treating or preventing the development of diabetes | NAN全球有限责任公司 | 2021-06-29 | — | — | CN | disclosed |
| US-20210186918-A1 | METHODS AND COMPOSITIONS FOR TREATING OBESITY, PREVENTING WEIGHT GAIN, PROMOTING WEIGHT LOSS, PROMOTING SLIMMING, OR TREATING OR PREVENTING THE DEVELOPMENT OF DIABETES | MOLECULE X LLC | 2021-06-24 | — | — | US | disclosed |
| US-10849872-B2 | Methods and compositions for treating obesity, preventing weight gain, promoting weight loss, promoting slimming, or treating or preventing the development of diabetes | NAN Global, LLC (US) | 2020-12-01 | — | — | US | disclosed |
| EP-3164125-A2 | METHODS AND COMPOSITIONS FOR TREATING OBESITY, PREVENTING WEIGHT GAIN, PROMOTING WEIGHT LOSS, PROMOTING SLIMMING, OR TREATING OR PREVENTING THE DEVELOPMENT OF DIABETES | Nan Global, LLC (US) | 2017-05-10 | — | — | EP | disclosed |
| EP-0614661-A2 | Benzylidene- and cinnamylidine-malononitrile derivatives for the inhibition of proliferative processes in mammalian cells | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 1994-09-14 | — | — | EP | disclosed |
| CN-1088083-A | Cosmetic composition | UNILEVER NV (NL) | 1994-06-22 | — | — | CN | disclosed |
| EP-0580409-A2 | Cosmetic composition containing DOPA derivatives | UNILEVER PLC (GB) | 1994-01-26 | — | — | EP | disclosed |
| EP-0572167-A1 | Cosmestic composition | UNILEVER PLC (GB) | 1993-12-01 | — | — | EP | disclosed |
| EP-0571198-A1 | Cosmetic composition containing hair-growth promoter | UNILEVER PLC (GB) | 1993-11-24 | — | — | EP | disclosed |
| EP-0517371-A2 | Hair growth composition containing citric acid esters | UNILEVER PLC (GB) | 1992-12-09 | — | — | EP | disclosed |
| US-5124354-A | Hair growth | CHESEBROUGH POND'S USA CO., DIVISION OF CONOPCO, INC. (US) | 1992-06-23 | — | — | US | disclosed |
| EP-0490581-A1 | Cosmetic composition | UNILEVER PLC (GB) | 1992-06-17 | — | — | EP | disclosed |
| EP-0322738-A2 | Benzylidene-malononitrile derivatives for the inhibition of proliferative processes in mammalian cells | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 1989-07-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210186918-A1 | METHODS AND COMPOSITIONS FOR TREATING OBESITY, PREVENTING WEIGHT GAIN, PROMOTING WEIGHT LOSS, PROMOTING SLIMMING, OR TREATING OR PREVENTING THE DEVELOPMENT OF DIABETES | GPR119, CPT1B, CPT2 | EGFR 3356/4885MEN1 3979/4885KMT2A 1054/4885 |
| US-20240066001-A1 | METHODS AND COMPOSITIONS FOR TREATING OBESITY, PREVENTING WEIGHT GAIN, PROMOTING WEIGHT LOSS, PROMOTING SLIMMING, OR TREATING OR PREVENTING THE DEVELOPMENT OF DIABETES | GPR119, CPT1B, CPT2 | EGFR 3356/4885MEN1 3979/4885KMT2A 1054/4885 |
| US-10849872-B2 | Methods and compositions for treating obesity, preventing weight gain, promoting weight loss, promoting slimming, or treating or preventing the development of diabetes | GPR119, CPT1B, CPT2 | EGFR 3356/4885MEN1 3979/4885KMT2A 1054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.